Shares of Aetna Inc (NYSE:AET) ended Friday session in green amid volatile trading. The shares closed up +0.63 points or 0.55% at $115.06 with XXXX million shares getting traded. Post opening the session at $114.00, the shares hit an intraday low of $113.97 and an intraday high of $115.44 and the price vacillated in this range throughout the day. The company has a market cap of $40.59 billion and the numbers of outstanding shares have been calculated to be 350.80 million shares.
On September 15, 2016 Despite spending more on health care than any other country in the world, Americans live shorter, less healthy lives than our counterparts in other high-income nations. While this is a national problem, our local communities are where we have the power to influence our health more than ever before.
To help improve our health through our communities, the Aetna Foundation, the American Public Health Association (APHA) and the National Association of Counties (NACo) recognized the HealthyCommunity50 that will move on to compete for the grand prize in the Healthiest Cities & Counties Challenge. These select cities and counties will receive a $10,000 community seed award to implement a program able to show measurable improvements around key social determinants of health.
“Approximately 90 percent of the factors affecting risk of premature death exist outside of a doctor’s office or hospital,” said Mark T. Bertolini, Aetna chairman and CEO. “The Healthiest Cities & Counties Challenge supports communities that are working to address and improve these factors and build a healthier world, community by community.”
The Challenge, a partnership between The Aetna Foundation, APHA and NACo, in collaboration with CEOs for Cities, is designed to create economically competitive, inclusive and equitable communities. The Challenge will award $1.5 million in prizes to small and mid-sized cities and counties that are able to show measurable improvements in health outcomes over the course of several years through cross-sector partnerships.
The Challenge is designed so that participants share successful health improvement strategies that can be scaled and replicated by other communities. HealthyCommunity50 members will share experiences and best practices throughout the competition via a learning network.
The HealthyCommunity50 were chosen out of hundreds of city governments, local municipalities, health departments, educational institutions and other entities. An expert advisory board selected these groups to continue to the next phase of the Challenge based on plans to improve the health of their communities. Improvements will be measured around at least one of five domains: healthy behaviors, community safety, built environment, social/economic factors and environmental exposures.
“We know that efforts to address these social determinants of health are necessary to create health equity, and that’s why we’re so excited for our 50 cities, counties and tribes,” said APHA executive director Georges C. Benjamin, MD. “Their innovative work is leading to better health in their own world and beyond.”
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) ended Friday session in red amid volatile trading. The shares closed down -0.16 points or -2.83% at $5.50 with 2.80 million shares getting traded. Post opening the session at $5.67, the shares hit an intraday low of $5.45 and an intraday high of $5.73 and the price vacillated in this range throughout the day. The company has a market cap of $704.05 million and the numbers of outstanding shares have been calculated to be 131.73 million shares.
ZIOPHARM Oncology Inc. (ZIOP) on Aug. 09, 2016 provided an update on the Company’s recent activities.
Corporate and Program Updates
Amended Exclusive Channel Collaborations with Intrexon to Improve Alignment as Programs Advance through Development. In June, ZIOPHARM and Intrexon Corporation (XON) announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and graft-versus-host-disease (GvHD) to improve alignment between both companies as ZIOPHARM broadens its pipeline and advances multiple therapeutic programs in the clinic.
Under the terms of the amendments:
- Operating profit rates payable to Intrexon from ZIOPHARM on products developed under its two existing collaborations will be reduced from 50% to 20%. This reduction will not apply to royalties or other payments made with respect to the companies’ existing collaboration with Merck Serono, the biopharmaceutical business of Merck KGaA;
- Economics from any future sublicensing arrangements with potential third party collaborators will remain evenly split.
In consideration of the amendments, ZIOPHARM has issued shares of a new class of preferred stock that carries an initial stated value of $120 million and a monthly dividend of 1%, payable in additional preferred shares. Only upon the first approval of a product in the United States or upon certain fundamental transactions, such as a change of control of ZIOPHARM, the preferred shares issued to Intrexon will be converted into ZIOPHARM common stock equal to the aggregate stated value divided by the volume weighted average closing price of ZIOPHARM’s common stock over the 20 trading days ending on the date that the product approval or such transaction is announced.